How long before xtampza becomes generic?

Short answer
Most experts expect generic Xtampza (oxycodone bitartrate, ER) to become available in the United States sometime in 2025‑2026—once the last of its patents and FDA‑granted exclusivities lapse and a qualified generic applicant gets FDA approval.

What determines the timing?

Current status (as of 2024)

1. Patent landscape – Pfizer’s most recent patents covering Xtampza’s extended‑release technology are set to expire late 2025. A few secondary patents (e.g., for specific manufacturing methods) extend into 2026, but those are less likely to block generic entry.
2. Regulatory exclusivity – The 5‑year market exclusivity granted for the original NDA expired in 2024, so no FDA‑mandated exclusivity period remains.
3. Generic filings – Several generic manufacturers (including some that already produce other oxycodone ER products) have filed ANDAs or are in the process of doing so. The FDA’s review timeline suggests that an approval could be granted by mid‑2025 if the filings are complete and no patent litigation blocks the process.
4. Potential delays – Patent litigation or “special‑ty” exclusivity claims (e.g., for new formulations) could postpone generic availability by a few months. However, the prevailing view is that late‑2025 to early‑2026 is the realistic window.

Practical take‑away

If you’re a prescriber or a patient planning for cost savings, it’s a good idea to keep an eye on FDA announcements and the status of generic filings. By the end of 2025, you should have a clear idea of whether generics will be on the market and, if so, which manufacturers are supplying them.